Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
36.70
+3.47 (10.44%)
At close: Apr 24, 2025, 4:00 PM
36.70
0.00 (0.00%)
After-hours: Apr 24, 2025, 7:50 PM EDT
Summit Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Summit Therapeutics stock have an average target of 35.44, with a low estimate of 30 and a high estimate of 44. The average target predicts a decrease of -3.43% from the current stock price of 36.70.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 26, 2025.
Analyst Ratings
The average analyst rating for Summit Therapeutics stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 4 | 5 | 6 | 6 |
| Buy | 1 | 2 | 2 | 2 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 6 | 7 | 8 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 23, 2025 |
| Citigroup | Citigroup | Hold → Strong Buy Upgrades $23 → $35 | Hold → Strong Buy | Upgrades | $23 → $35 | -4.63% | Mar 26, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Mar 21, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $30 | Buy | Initiates | $30 | -18.26% | Mar 12, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $42 | Strong Buy | Initiates | $42 | +14.44% | Feb 28, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
45.90M
EPS This Year
-0.42
from -0.31
EPS Next Year
-0.58
from -0.42
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 174.1M | 449.4M | ||
| Avg | n/a | 45.9M | 145.6M | ||
| Low | n/a | n/a | 9.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 879.1% | ||
| Avg | - | - | 217.2% | ||
| Low | - | - | -78.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.41 | -0.47 | -0.29 | ||
| Avg | -0.42 | -0.58 | -0.58 | ||
| Low | -0.46 | -0.70 | -0.86 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.